Jerry G. Myers

Jerry G. Myers

Auto-generated profile, based on publicly available information

Jerry G. Myers

Affiliations Committee on Credible Practice of Modeling, & Simulation in Healthcare, Interagency Modeling and Analysis Group and Multiscale Modeling Consortium, Bethesda, Maryland United States of America, NASA - John H Glenn Research Center, Cleveland, Ohio, United States of America

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2014 in Life
Verified
Journal Article
Open access
PDF file
ENEmily Nelson
Emily Nelson
LMLealem Mulgueta
Lealem Mulgueta
JMJerry G. Myers
Jerry G. Myers
Although changes to visual acuity in spaceflight have been observed in some astronauts since the early days of the space program, the impact to the crew was considered minor. Since that time, missions to the International Space Station have extended the typical duration of time spent in microgravity from a few days or weeks to many months. This has been accompanied by the emergence of a variety of ophthalmic pathologies in a significant proportion of long-duration crewmembers, including globe flattening, choroidal folding, optic disc edema, and optic nerve kinking, among others. The clinical findings of affected astronauts are reminiscent of terrestrial pathologies such as idiopathic intracranial hypertension that are characterized by high intracranial pressure. As a result, NASA has placed an emphasis on determining the relevant factors and their interactions that are responsible for detrimental ophthalmic response to space. This article will describe the Visual Impairment and Intracranial Pressure syndrome, link it to key factors in physiological adaptation to the microgravity environment, particularly a cephalad shifting of bodily fluids, and discuss the implications for ocular biomechanics and physiological function in long-duration spaceflight.

29 September 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
AEAhmet Erdemir
Ahmet Erdemir
LMLealem Mulugeta
Lealem Mulugeta
JKJoy P. Ku
Joy P. Ku
ADAndrew Drach
Andrew Drach
MHMarc Horner
Marc Horner
JMJerry G. Myers
Jerry G. Myers
The complexities of modern biomedicine are rapidly increasing. Thus, modeling and simulation have become increasingly important as a strategy to understand and predict the trajectory of pathophysiology, disease genesis, and disease spread in support of clinical and policy decisions. In such cases, inappropriate or ill-placed trust in the model and simulation outcomes may result in negative outcomes, and hence illustrate the need to formalize the execution and communication of modeling and simulation practices. Although verification and validation have been generally accepted as significant components of a model’s credibility, they cannot be assumed to equate to a holistic credible practice, which includes activities that can impact comprehension and in-depth examination inherent in the development and reuse of the models. For the past several years, the Committee on Credible Practice of Modeling and Simulation in Healthcare, an interdisciplinary group seeded from a U.S. interagency initiative, has worked to codify best practices. Here, we provide Ten Rules for credible practice of modeling and simulation in healthcare developed from a comparative analysis by the Committee’s multidisciplinary membership, followed by a large stakeholder community survey. These rules establish a unified conceptual framework for modeling and simulation design, implementation, evaluation, dissemination and usage across the modeling and simulation life-cycle. While biomedical science and clinical care domains have somewhat different requirements and expectations for credible practice, our study converged on rules that would be useful across a broad swath of model types. In brief, the rules are: (1) Define context clearly. (2) Use contextually appropriate data. (3) Evaluate within context. (4) List limitations explicitly. (5) Use version control. (6) Document appropriately. (7) Disseminate broadly. (8) Get independent reviews. (9) Test competing implementations. (10) Conform to standards. Although some of these are common sense guidelines, we have found that many are often missed or misconstrued, even by seasoned practitioners. Computational models are already widely used in basic science to generate new biomedical knowledge. As they penetrate clinical care and healthcare policy, contributing to personalized and precision medicine, clinical safety will require established guidelines for the credible practice of modeling and simulation in healthcare.

31 March 2022 in npj Microgravity
Verified
Journal Article
Open access
PDF file
EAErik L. Antonsen
Erik L. Antonsen
JMJerry G. Myers
Jerry G. Myers
LBLynn Boley
Lynn Boley
JAJohn Arellano
John Arellano
EKEric Kerstman
Eric Kerstman
MBMary Van Baalen
Mary Van Baalen
NASA and commercial spaceflight companies will soon be retuning humans to the Moon and then eventually sending them on to Mars. These distant planetary destinations will pose new risks—in particular for the health of the astronaut crews. The bulk of the evidence characterizing human health and performance in spaceflight has come from missions in Low Earth Orbit. As missions last longer and travel farther from Earth, medical risk is expected to contribute an increasing proportion of total mission risk. To date, there have been no reliable estimates of how much. The Integrated Medical Model (IMM) is a Probabilistic Risk Assessment (PRA) Monte-Carlo simulation tool developed by NASA for medical risk assessment. This paper uses the IMM to provide an evidence-based, quantified medical risk estimate comparison across different spaceflight mission durations. We discuss model limitations and unimplemented capabilities providing insight into the complexity of medical risk estimation for human spaceflight. The results enable prioritization of medical needs in the context of other mission risks. These findings provide a reasonable bounding estimate for medical risk in missions to the Moon and Mars and hold value for risk managers and mission planners in performing cost-benefit trades for mission capability and research investments.

23 March 2023 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
RSRyan T. Scott
Ryan T. Scott
LSLauren M. Sanders
Lauren M. Sanders
EAErik L. Antonsen
Erik L. Antonsen
JHJaden J. A. Hastings
Jaden J. A. Hastings
SPSeung-min Park
Seung-min Park
Sylvain CostesSylvain Costes
Sylvain Costes

23 March 2023 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
LSLauren M. Sanders
Lauren M. Sanders
RSRyan T. Scott
Ryan T. Scott
JYJason H. Yang
Jason H. Yang
AQAmina Ann Qutub
Amina Ann Qutub
HMHector Garcia Martin
Hector Garcia Martin
Sylvain CostesSylvain Costes
Sylvain Costes

18 March 2010 in Theoretical Biology and Medical Modelling
Verified
Journal Article
Open access
PDF file
RSRichard L Summers
Richard L Summers
SPSteven Platts
Steven Platts
JMJerry G Myers
Jerry G Myers
TCThomas G Coleman
Thomas G Coleman
A tendency to develop reentry orthostasis after a prolonged exposure to microgravity is a common problem among astronauts. The problem is 5 times more prevalent in female astronauts as compared to their male counterparts. The mechanisms responsible for this gender differentiation are poorly understood despite many detailed and complex investigations directed toward an analysis of the physiologic control systems involved.